A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease

A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease

Reported levels of amyloid-beta and tau in human cerebrospinal fluid (CSF) were evaluated to discover if these biochemical markers can predict the transition from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD). A systematic review of the literature in PubMed and Web of Science (April 20...

Full description

Bibliographic Details
Main Authors:	Yunxing Ma, Julia Brettschneider, Joanna F. Collingwood
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Biomedicines
Subjects:	Alzheimer’s disease cerebrospinal fluid tau amyloid beta mild cognitive impairment biomarker
Online Access:	https://www.mdpi.com/2227-9059/10/7/1713

Similar Items

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
by: Jung Eun Park, et al.
Published: (2019-03-01)

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
by: Feng Xing, et al.
Published: (2021-06-01)

Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis
by: Zsolt Huszár, et al.
Published: (2024-04-01)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
by: Katherine W. Turk, et al.
Published: (2022-02-01)

From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer’s Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients
by: Ioanna Tsantzali, et al.
Published: (2021-10-01)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
by: Caterina Motta, et al.
Published: (2023-08-01)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
by: Lauren E. McCollum, et al.
Published: (2021-01-01)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
by: Yuk Yee Leung, et al.
Published: (2015-09-01)

Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
by: Ching-Chi Hsu, et al.
Published: (2024-03-01)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
by: George P. Paraskevas, et al.
Published: (2021-09-01)

Cerebrospinal fluid levels of amyloid beta 1-43 in patients with amnestic mild cognitive impairment or early Alzheimer’s disease: a 2-year follow-up study
by: Camilla eLauridsen, et al.
Published: (2016-03-01)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
by: Giovanni Bellomo, et al.
Published: (2021-03-01)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
by: Franc Llorens, et al.
Published: (2017-09-01)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
by: Tyler S. Saunders, et al.
Published: (2022-09-01)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
by: Donovan A. McGrowder, et al.
Published: (2021-02-01)

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia
by: Lutz Frölich, et al.
Published: (2017-10-01)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß1−42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
by: Emmanuelle Duron, et al.
Published: (2019-02-01)

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
by: Patel Sunil, et al.
Published: (2012-03-01)

Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition
by: Mattia Trunfio, et al.
Published: (2022-04-01)

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
by: Fangyang Jiao, et al.
Published: (2023-02-01)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
by: Nicholas J. Ashton, et al.
Published: (2022-02-01)

Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer’s disease and other neurodegenerative diseases
by: Masanori Kurihara, et al.
Published: (2024-03-01)

Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease
by: Omar A. Halawa, et al.
Published: (2019-01-01)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
by: Emmanuelle Duron, et al.
Published: (2018-10-01)

Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders
by: Wataru Araki, et al.
Published: (2017-09-01)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
by: Mahsa Dolatshahi, et al.
Published: (2018-07-01)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
by: Nicolas R. Barthélemy, et al.
Published: (2020-03-01)

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
by: Santiago Bullich, et al.
Published: (2022-07-01)

Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease
by: Kyu Hwan Shim, et al.
Published: (2022-12-01)

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
by: Cristina d’Abramo, et al.
Published: (2020-09-01)

A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment
by: Marco Vinceti, et al.
Published: (2017-12-01)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
by: Alejandro R Roda, et al.
Published: (2022-01-01)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01)

Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
by: Syed Haris Omar, et al.
Published: (2020-07-01)

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
by: Zdeněk Fišar
Published: (2022-11-01)

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
by: Alex Zabala-Findlay, et al.
Published: (2023-04-01)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
by: Said HM, et al.
Published: (2022-04-01)

Interaction between Aβ and tau on reversion and conversion in mild cognitive impairment patients: After 2-year follow-up
by: Jinzhi Tang, et al.
Published: (2024-03-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)